First-ever Optical Blood Pressure Monitoring System Now Available in the United Kingdom. Aktiia’s clinically validated Optical Blood Pressure Monitoring technology estimates blood pressure accurately, automatically, and painlessly, by analyzing signals from the wearer’s wrist.
Digital health veteran, Michael Kisch, joins innovative automated blood pressure monitoring pioneer.
Aktiia, a Swiss-US startup, has developed a wrist-worn optical blood pressure monitor that can automatically take measurements around the clock without requiring a specific arm position.
Aktiia, a Swiss-US startup that has developed an optical blood pressure monitor at the wrist, has raised an additional CHF 6 million in funding to bring its product to market.
“Aktiia, the world’s first automated 24/7 blood pressure monitoring system, is now available in Ireland. The wearable device collects data during the day and while sleeping, providing comprehensive insights into blood pressure patterns that will better inform the diagnosis and management of hypertension. ”
“The system is ideal for someone who wants to keep a closer eye on their cardiovascular health. It can also be useful for those that are at risk for or have already been diagnosed with high blood pressure. The wearable provides a great tool to help you make lifestyle changes that benefit your cardiovascular health”
“What’s makes this particularly impressive is that these readings meet the ISO81060-2 standard for accuracy. The wearable has the CE marking as a Class IIa medical device. Which means the measurements are taken with clinical (cuff-like) accuracy.”
“The device doesn’t work like traditional blood pressure monitors. Rather than squeezing your arm each time it needs a measurement, the Aktiia Optical Blood Pressure Monitor monitors your blood pressure by analyzing the diameter of the blood vessels with each heartbeat. This happens automatically, so users are never aware of the test, and therefore do not skew the results by being anxious or behaving differently.”
“Britons who need to monitor their blood pressure will be the first in the world to be able to do so via a wearable device at home, thanks to a start-up business that has beaten the likes of Apple and Fitbit to crack this corner of the medical market.”
“Maker of wearable continuous blood pressure monitor, Aktiia, today launched their 24/7 automated blood pressure monitoring system that gathers data during the day and while the user is asleep. Aktiia has received its CE mark as a Class lla medical device, meaning that the device has been assessed to meet safety, health and environmental protection requirements in Europe.”
“Accurate and validated Cuffless products like Aktiia are big step forward and represent the future of how blood pressure will be monitored outside a physician’s office.”
“Swiss startup Aktiia has beaten Fitbit, Apple and other tech giants to become the first company to get regulatory approval to sell a wearable bracelet which measures blood pressure.”
“Solà predicts that the bracelet could eventually be a game-changer for ambulatory blood pressure monitoring (ABPM), where overnight readings could be taken without the discomfort and disruption of periodic cuff inflations with current systems.”
“Aktiia’s bracelet and algorithms have now been validated in clinical trials against arterial lines (the gold standard for clinical reference) and in ambulatory settings. Never before has it been possible to measure blood pressure profiles, at any time, over long periods. This valuable and unique dataset will allow for broader insights into the diagnosis and treatment of hypertension, the largest epidemic of humankind.”
“Cuff-less blood pressure monitor company Aktiia scored $6.1 million (CHF 6 million Swiss francs) in its second funding round. Redalpline led the funding round with participation from Translink Capital, Investiere, Libra, Christian Wenger, Spark Street Capital and Barbaric Holdings.”
“A wrist-based optical blood pressure monitor has the potential to replace cuff monitoring systems for ambulatory blood pressure, suggests a study in the journal Blood Pressure Monitoring.”
“The experimental data of this initial study showed error figures within 1 ± 7 mmHg, which are smaller than the threshold of 5 ± 8 mmHg typically accepted in clinical investigations… Having an optical, non-invasive, and cuffless blood pressure monitoring technology would improve the lives of many patients.”